On this page
Cerebral creatine deficiency (SLC6A8)
This condition is caused by changes in the SLC6A8 gene, impacting how creatine, an important energy molecule, is transported into brain cells. It typically leads to developmental delays and neurological challenges, predominantly in males.
Available at Jeen Health
Clinical tests that include this
Overview
Cerebral creatine deficiency due to SLC6A8 deficiency is an X-linked inherited metabolic disorder. It affects the body's ability to transport creatine, a crucial molecule for energy storage and use, particularly within the brain [PMID:24510002]. When creatine cannot efficiently enter brain cells, these cells lack the energy they need to function correctly, leading to a range of neurological issues. The condition is more commonly observed in males due to its X-linked inheritance pattern.
Symptoms & clinical features
The symptoms of cerebral creatine deficiency (SLC6A8) can vary but typically include developmental delay, affecting speech and motor skills. Individuals may experience intellectual disability, which can range from mild to severe. Behavioural difficulties, such as autistic-like features, attention deficit hyperactivity disorder (ADHD), and hyperactivity, are also commonly reported [PMID:29658249]. Seizures may occur in some affected individuals.
Muscle weakness or hypotonia (reduced muscle tone) can also be present. The severity of these symptoms can differ significantly between individuals, even within the same family.
Video: Genetics 101
Affected organs
The primary organ affected by SLC6A8 deficiency is the brain. Creatine is vital for maintaining energy levels within brain cells. Without adequate creatine transport, these cells cannot function optimally, leading to the observed neurological and developmental difficulties. Other body systems are generally not directly affected, although muscle involvement can occur due to the systemic role of creatine.
Risks & severity
The severity of cerebral creatine deficiency (SLC6A8) can range from moderate to severe, with most affected males experiencing significant developmental and intellectual challenges. The condition typically presents in early childhood when developmental milestones are missed or delayed. Intellectual disability and speech impairment are common features, often becoming apparent as a child grows.
The exact prevalence is not well established but is estimated to affect around 1 in 100,000 males. Females who carry a pathogenic variant in SLC6A8 are generally unaffected or have milder symptoms, such as learning difficulties, due to X-inactivation patterns, though some may experience more significant symptoms [PMID:24510002].
Genetic causes
Cerebral creatine deficiency (SLC6A8) is caused by pathogenic variants in the SLC6A8 gene. This gene provides instructions for making a protein called the creatine transporter. The creatine transporter is responsible for moving creatine from the bloodstream into cells, especially those in the brain, where it is essential for energy metabolism.
When there is a pathogenic variant in SLC6A8, the creatine transporter protein may be absent, reduced, or non-functional. This prevents creatine from effectively entering brain cells, leading to a deficiency of creatine within the brain. This lack of creatine disrupts the normal energy supply to brain cells, resulting in the neurological symptoms associated with the condition.
- SLC6A8 solute carrier family 6 member 8The SLC6A8 gene provides instructions for creating a transporter protein crucial for moving creatine into cells, a process vital for proper energy storage and utilisation within the body.
Inheritance pattern
Cerebral creatine deficiency (SLC6A8) has an X-linked recessive inheritance pattern. This means the SLC6A8 gene is located on the X chromosome.
Males have one X and one Y chromosome, so if they inherit an X chromosome with a pathogenic SLC6A8 variant, they will typically develop the condition. Females have two X chromosomes; if one X chromosome carries a pathogenic variant, the other X chromosome can often compensate, meaning they are usually carriers and may not show symptoms, or have milder ones. However, depending on X-inactivation, some female carriers can experience a range of symptoms, including intellectual disability. A male with the condition cannot pass it to his sons, but all his daughters will be carriers. Female carriers have a 50% chance with each pregnancy of passing the pathogenic variant to their child. Sons who inherit the variant will be affected, and daughters who inherit it will be carriers.
X-linked recessive: sons of a carrier mother have a 50% chance of being affected. Daughters have a 50% chance of being carriers.
Diagnosis & testing
Diagnosis of cerebral creatine deficiency (SLC6A8) typically begins with clinical suspicion based on the presence of developmental delay, intellectual disability, and other neurological symptoms. Initial investigations may include magnetic resonance imaging (MRI) of the brain and magnetic resonance spectroscopy (MRS), which can show reduced creatine levels in the brain [PMID:24510002].
Confirmation of the diagnosis involves genetic testing to identify pathogenic variants in the SLC6A8 gene. Genetic testing for this condition is available through the NHS Genomic Medicine Service, often initiated following a referral from a paediatrician or clinical geneticist. This testing falls under specific R-codes, allowing for comprehensive genetic analysis.
Management & lifestyle
Management for individuals with cerebral creatine deficiency (SLC6A8) focuses on supportive care and symptom management. This often involves a multidisciplinary team approach including paediatricians, neurologists, geneticists, speech and language therapists, occupational therapists, physiotherapists, and educational psychologists.
While there is no cure, some individuals may benefit from creatine supplementation, though its effectiveness can vary and brain creatine levels may not always normalise due to the transport defect. Management strategies aim to optimise development, manage seizures if present, and provide appropriate educational and behavioural support. Regular follow-up with healthcare professionals is important to monitor progress and adjust interventions as needed.
UK care pathway
In the UK, suspected cases of cerebral creatine deficiency (SLC6A8) are typically referred to specialist NHS Genomic Medicine Service centres. A paediatrician or neurologist would usually make this referral to a clinical genetics team. Genetic testing, often guided by PanelApp R-codes, confirms the diagnosis, and a genetic counsellor can provide essential information and support regarding inheritance patterns and family planning implications.
Frequently asked questions
What is creatine and why is it important for the brain?
Creatine is a natural compound that plays a vital role in providing energy to cells, especially those with high energy demands like muscle and brain cells. In the brain, creatine helps maintain a stable energy supply, which is crucial for normal brain function and development.
How is cerebral creatine deficiency (SLC6A8) inherited?
This condition has an X-linked recessive inheritance pattern. This means the gene responsible, SLC6A8, is on the X chromosome. Males are typically more severely affected because they have only one X chromosome, while females with two X chromosomes often remain carriers or have milder symptoms.
Can females be affected by SLC6A8 deficiency?
Yes, females can be affected, though typically less severely than males. Due to having two X chromosomes, one usually compensates for the other. However, depending on complex genetic factors like X-inactivation, some females can experience learning difficulties or, in rare cases, more pronounced symptoms. They are also carriers and can pass the condition on.
Is there a treatment for cerebral creatine deficiency (SLC6A8)?
While there is no cure, management focuses on supportive care and optimising development. This may include therapies like speech and language therapy, occupational therapy, and educational support. Creatine supplementation may be considered in some cases, although its effectiveness in normalising brain creatine levels can vary.
How is this condition diagnosed in the UK?
Diagnosis in the UK typically involves a referral to a clinical genetics service after initial investigations suggest the condition. Magnetic resonance spectroscopy (MRS) can show low brain creatine, and the diagnosis is confirmed by genetic testing through the NHS Genomic Medicine Service to identify pathogenic variants in the SLC6A8 gene.